Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 Inhibitor in Advanced pMMR/MSS Colorectal Cancer
NCT06391905Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- May 2024
- Primary completion
- Apr 2028
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Objective Response Rate at 5 years. Planned start May 2024; status: not yet recruiting.
02
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06391905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391905.